175 related articles for article (PubMed ID: 38237027)
1. Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models.
Ma W; Wei S; Li Q; Zeng J; Xiao W; Zhou C; Yoneda KY; Zeki AA; Li T
Mol Cancer Ther; 2024 May; 23(5):700-710. PubMed ID: 38237027
[TBL] [Abstract][Full Text] [Related]
2. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma.
Lu GS; Li M; Xu CX; Wang D
Cell Death Dis; 2018 Oct; 9(11):1111. PubMed ID: 30382076
[TBL] [Abstract][Full Text] [Related]
3. Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma.
Tohmé R; Izadmehr S; Gandhe S; Tabaro G; Vallabhaneni S; Thomas A; Vasireddi N; Dhawan NS; Ma'ayan A; Sharma N; Galsky MD; Ohlmeyer M; Sangodkar J; Narla G
JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830869
[TBL] [Abstract][Full Text] [Related]
4. Methyltransferase like 7B is a potential therapeutic target for reversing EGFR-TKIs resistance in lung adenocarcinoma.
Song H; Liu D; Wang L; Liu K; Chen C; Wang L; Ren Y; Ju B; Zhong F; Jiang X; Wang G; Chen ZS; Zou C
Mol Cancer; 2022 Feb; 21(1):43. PubMed ID: 35144642
[TBL] [Abstract][Full Text] [Related]
5. Shisa3 brakes resistance to EGFR-TKIs in lung adenocarcinoma by suppressing cancer stem cell properties.
Si J; Ma Y; Bi JW; Xiong Y; Lv C; Li S; Wu N; Yang Y
J Exp Clin Cancer Res; 2019 Dec; 38(1):481. PubMed ID: 31801598
[TBL] [Abstract][Full Text] [Related]
6. Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance.
Kita K; Fukuda K; Takahashi H; Tanimoto A; Nishiyama A; Arai S; Takeuchi S; Yamashita K; Ohtsubo K; Otani S; Yanagimura N; Suzuki C; Ikeda H; Tamura M; Matsumoto I; Yano S
Cancer Sci; 2019 Oct; 110(10):3215-3224. PubMed ID: 31432603
[TBL] [Abstract][Full Text] [Related]
7. NOTCH3 Overexpression and Posttranscriptional Regulation by miR-150 Were Associated With EGFR-TKI Resistance in Lung Adenocarcinoma.
Zhang Y; Chen B; Wang Y; Zhao Q; Wu W; Zhang P; Miao L; Sun S
Oncol Res; 2019 Jul; 27(7):751-761. PubMed ID: 30732676
[TBL] [Abstract][Full Text] [Related]
8. Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma.
Hong X; Hsieh MT; Tseng TY; Lin HY; Chang HC; Yau ST; Cheng WC; Ke B; Liao HH; Wu CY; Liu AA; Wu MM; Huang KY; Yang PC; Kuo SC; Hung MC; Lee PC
J Biol Chem; 2023 Jun; 299(6):104814. PubMed ID: 37178919
[TBL] [Abstract][Full Text] [Related]
9. A real-world study and network pharmacology analysis of EGFR-TKIs combined with ZLJT to delay drug resistance in advanced lung adenocarcinoma.
Han X; Liang L; He C; Ren Q; Su J; Cao L; Zheng J
BMC Complement Med Ther; 2023 Nov; 23(1):422. PubMed ID: 37990309
[TBL] [Abstract][Full Text] [Related]
10. AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells.
Kim D; Bach DH; Fan YH; Luu TT; Hong JY; Park HJ; Lee SK
Cell Death Dis; 2019 May; 10(5):361. PubMed ID: 31043587
[TBL] [Abstract][Full Text] [Related]
11. Small Molecule T315 Promotes Casitas B-Lineage Lymphoma-Dependent Degradation of Epidermal Growth Factor Receptor via Y1045 Autophosphorylation.
Huang KY; Kao SH; Wang WL; Chen CY; Hsiao TH; Salunke SB; Chen JJ; Su KY; Yang SC; Hong TM; Chen CS; Yang PC
Am J Respir Crit Care Med; 2016 Apr; 193(7):753-66. PubMed ID: 26583948
[TBL] [Abstract][Full Text] [Related]
12. A novel protein encoded by circASK1 ameliorates gefitinib resistance in lung adenocarcinoma by competitively activating ASK1-dependent apoptosis.
Wang T; Liu Z; She Y; Deng J; Zhong Y; Zhao M; Li S; Xie D; Sun X; Hu X; Chen C
Cancer Lett; 2021 Nov; 520():321-331. PubMed ID: 34389432
[TBL] [Abstract][Full Text] [Related]
13. Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis.
Lou Y; Xu J; Zhang Y; Zhang W; Zhang X; Gu P; Zhong H; Wang H; Lu J; Han B
Cell Death Dis; 2021 Feb; 12(2):170. PubMed ID: 33568630
[TBL] [Abstract][Full Text] [Related]
14. Hsa_circ_0005576 promotes osimertinib resistance through the miR-512-5p/IGF1R axis in lung adenocarcinoma cells.
Liu S; Jiang Z; Xiao P; Li X; Chen Y; Tang H; Chai Y; Liu Y; Zhu Z; Xie Q; He W; Ma Y; Jin L; Feng W
Cancer Sci; 2022 Jan; 113(1):79-90. PubMed ID: 34706132
[TBL] [Abstract][Full Text] [Related]
15. Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.
Kang DH; Jung SS; Yeo MK; Lee DH; Yoo G; Cho SY; Oh IJ; Kim JO; Park HS; Chung C; Lee JE
BMC Cancer; 2020 Jun; 20(1):571. PubMed ID: 32552717
[TBL] [Abstract][Full Text] [Related]
16. Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors.
Morgillo F; Cascone T; D'Aiuto E; Martinelli E; Troiani T; Saintigny P; De Palma R; Heymach JV; Berrino L; Tuccillo C; Ciardiello F
Br J Cancer; 2011 Jul; 105(3):382-92. PubMed ID: 21750552
[TBL] [Abstract][Full Text] [Related]
17. Targeting YAP-p62 signaling axis suppresses the EGFR-TKI-resistant lung adenocarcinoma.
Park HS; Lee DH; Kang DH; Yeo MK; Bae G; Lee D; Yoo G; Kim JO; Moon E; Huh YH; Lee SH; Jo EK; Cho SY; Lee JE; Chung C
Cancer Med; 2021 Feb; 10(4):1405-1417. PubMed ID: 33486901
[TBL] [Abstract][Full Text] [Related]
18. Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas.
Lee TF; Tseng YC; Nguyen PA; Li YC; Ho CC; Wu CW
Sci Rep; 2018 Jan; 8(1):271. PubMed ID: 29321482
[TBL] [Abstract][Full Text] [Related]
19. PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation.
Wu DW; Wu TC; Chen CY; Lee H
Clin Cancer Res; 2016 Nov; 22(21):5370-5382. PubMed ID: 27178741
[TBL] [Abstract][Full Text] [Related]
20. Alterations in the Global Proteome and Phosphoproteome in Third Generation EGFR TKI Resistance Reveal Drug Targets to Circumvent Resistance.
Zhang X; Maity TK; Ross KE; Qi Y; Cultraro CM; Bahta M; Pitts S; Keswani M; Gao S; Nguyen KDP; Cowart J; Kirkali F; Wu C; Guha U
Cancer Res; 2021 Jun; 81(11):3051-3066. PubMed ID: 33727228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
